

# Daniel Tak Mao Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4069104/publications.pdf>

Version: 2024-02-01

209  
papers

10,588  
citations

47006  
47  
h-index

39675  
94  
g-index

266  
all docs

266  
docs citations

266  
times ranked

9930  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis. <i>New England Journal of Medicine</i> , 2000, 343, 1156-1162.	27.0	905
2	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	5.2	782
3	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
4	Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus. <i>PLoS Genetics</i> , 2010, 6, e1000841.	3.5	378
5	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.	7.4	376
6	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	5.2	325
7	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 128-139.	11.4	223
8	Survival analysis and causes of mortality in patients with lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3248-3254.	0.7	222
9	Roxadustat (FG-4592). <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1225-1233.	6.1	216
10	Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. <i>Cell</i> , 2021, 184, 2212-2228.e12.	28.9	216
11	Meta-analysis Followed by Replication Identifies Loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as Associated with Systemic Lupus Erythematosus in Asians. <i>American Journal of Human Genetics</i> , 2013, 92, 41-51.	6.2	184
12	Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays. <i>Hepatology</i> , 1993, 17, 5-8.	7.3	180
13	Pathophysiological Changes to the Peritoneal Membrane during PD-Related Peritonitis: The Role of Mesothelial Cells. <i>Mediators of Inflammation</i> , 2012, 2012, 1-21.	3.0	178
14	DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. <i>Journal of Autoimmunity</i> , 2014, 54, 127-136.	6.5	172
15	Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. <i>Hepatology</i> , 2002, 36, 1246-1252.	7.3	151
16	Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. <i>Lupus</i> , 2005, 14, 265-272.	1.6	141
17	Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 2000, 35, 644-652.	1.9	139
18	Anti-dsDNA Antibodies Bind to Mesangial Annexin II in Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1912-1927.	6.1	136

#	ARTICLE	IF	CITATIONS
19	Mechanisms of Kidney Injury in Lupus Nephritis – the Role of Anti-dsDNA Antibodies. <i>Frontiers in Immunology</i> , 2015, 6, 475.	4.8	112
20	ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. <i>Human Molecular Genetics</i> , 2009, 18, 2063-2070.	2.9	104
21	Anti-DNA antibodies in the pathogenesis of lupus nephritis – The emerging mechanisms. <i>Autoimmunity Reviews</i> , 2008, 7, 317-321.	5.8	103
22	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	7.4	103
23	B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis – Role in Pathogenesis and Effect of Immunosuppressive Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6231.	4.1	88
24	ELF1 is associated with systemic lupus erythematosus in Asian populations. <i>Human Molecular Genetics</i> , 2011, 20, 601-607.	2.9	78
25	Treatment of severe lupus nephritis: the new horizon. <i>Nature Reviews Nephrology</i> , 2015, 11, 46-61.	9.6	78
26	Autoantibodies and Resident Renal Cells in the Pathogenesis of Lupus Nephritis: Getting to Know the Unknown. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-13.	3.3	76
27	Risks and Outcomes of Peritonitis after Flexible Colonoscopy in CAPD Patients. <i>Peritoneal Dialysis International</i> , 2007, 27, 560-564.	2.3	74
28	Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2768-2776.	0.7	73
29	Effect of Human Anti-DNA Antibodies on Proximal Renal Tubular Epithelial Cell Cytokine Expression. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3281-3294.	6.1	72
30	Lupus Nephritis in Asia: Clinical Features and Management. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 100-109.	2.5	67
31	Pilot 24-month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. <i>Nephrology</i> , 2012, 17, 352-357.	1.6	66
32	Roxadustat for CKD-related Anemia in Non-dialysis Patients. <i>Kidney International Reports</i> , 2021, 6, 624-635.	0.8	65
33	Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 2001, 38, 1055-1060.	1.9	64
34	Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. <i>Nephrology</i> , 2007, 12, 576-581.	1.6	64
35	Increased expression of TLR2 in CD4 <sup>+</sup> T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications. <i>European Journal of Immunology</i> , 2015, 45, 2683-2693.	2.9	63
36	Intrinsic Cells: Mesothelial Cells – Central Players in Regulating Inflammation and Resolution. <i>Peritoneal Dialysis International</i> , 2009, 29, 21-27.	2.3	61

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcome of Renal Transplant Recipients With Chronic Hepatitis B Infectionâ€”Impact of Antiviral Treatments. Transplantation, 2010, 90, 325-330.	1.0	59
38	Overview of lupus nephritis management guidelines and perspective from <scp>A</scp>ia. Nephrology, 2014, 19, 11-20.	1.6	59
39	Enhanced Psychosocial Support for Caregiver Burden forÂPatients With Chronic Kidney Failure Choosing NotÂtoÂBeÂTreated by Dialysis or Transplantation: A Pilot Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 67, 585-592.	1.9	59
40	Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. Nephrology Dialysis Transplantation, 2005, 20, 1336-1349.	0.7	55
41	Recent knowledge on the pathophysiology of septic acute kidney injury: A narrative review. Journal of Critical Care, 2016, 31, 82-89.	2.2	54
42	Anti-dsDNA antibodies and resident renal cells â€” Their putative roles in pathogenesis of renal lesions in lupus nephritis. Clinical Immunology, 2017, 185, 40-50.	3.2	54
43	Antiâ€DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis and Rheumatism, 2009, 60, 2071-2082.	6.7	53
44	Peritoneal mesothelial cell culture and biology. Peritoneal Dialysis International, 2006, 26, 162-73.	2.3	53
45	Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 147-153.	4.5	50
46	Hepatitis B and Renal Disease. Current Hepatitis Reports, 2010, 9, 99-105.	0.3	49
47	Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology, 2013, 52, 480-486.	1.9	49
48	Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-Î³ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Science and Medicine, 2017, 4, e000226.	2.7	49
49	Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. Journal of Rheumatology, 2018, 45, 1663-1670.	2.0	48
50	Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney International, 2003, 64, 519-533.	5.2	46
51	E4BP4 overexpression: A protective mechanism in CD4+ T cells from SLE patients. Journal of Autoimmunity, 2013, 41, 152-160.	6.5	46
52	Cellular Cholesterol Transport Proteins in Diabetic Nephropathy. PLoS ONE, 2014, 9, e105787.	2.5	46
53	Syndecanâ€4 upâ€regulation in proliferative renal disease is related to microfilament organization. FASEB Journal, 2001, 15, 1631-1633.	0.5	45
54	The effect of mycophenolic acid on epigenetic modifications in lupus CD4+T cells. Clinical Immunology, 2015, 158, 67-76.	3.2	45

#	ARTICLE	IF	CITATIONS
55	Peripheral whole blood FOXP3 TSDR methylation: a potential marker in severity assessment of autoimmune diseases and chronic infections. <i>Immunological Investigations</i> , 2015, 44, 126-136.	2.0	45
56	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. <i>Arthritis and Rheumatology</i> , 2019, 71, 411-419.	5.6	45
57	Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF- $\beta$ 1 and collagen synthesis. <i>Journal of Autoimmunity</i> , 2015, 58, 111-122.	6.5	43
58	Pathophysiology of the Peritoneal Membrane during Peritoneal Dialysis: The Role of Hyaluronan. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-11.	3.0	42
59	Long-term data on tacrolimus treatment in lupus nephritis. <i>Rheumatology</i> , 2014, 53, 2232-2237.	1.9	42
60	Septic acute kidney injury in critically ill patients – a single-center study on its incidence, clinical characteristics, and outcome predictors. <i>Renal Failure</i> , 2016, 38, 706-716.	2.1	42
61	mTOR Inhibition and Kidney Diseases. <i>Transplantation</i> , 2018, 102, S32-S40.	1.0	42
62	Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70S6K with Dendrimer Nanovector-Based siRNA Delivery. <i>Molecular Therapy</i> , 2018, 26, 70-83.	8.2	42
63	Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience. <i>Nephrology</i> , 2012, 17, 676-680.	1.6	41
64	Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese. <i>Rheumatology</i> , 2013, 52, 337-345.	1.9	41
65	Mediators of Inflammation and Their Effect on Resident Renal Cells: Implications in Lupus Nephritis. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-10.	3.3	40
66	Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified Hypomethylation in Genes Related to the Type I Interferon Pathway. <i>PLoS ONE</i> , 2017, 12, e0169553.	2.5	40
67	Immunogenicity of Intradermal Hepatitis B Vaccination in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2002, 2, 965-969.	4.7	38
68	Effect of rapamycin on renal ischemia-reperfusion injury in mice. <i>Transplant International</i> , 2006, 19, 834-839.	1.6	38
69	A Possible Role of HMGB1 in DNA Demethylation in CD4 <sup>+</sup> T Cells from Patients with Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-5.	3.3	37
70	Longterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years. <i>Journal of Rheumatology</i> , 2017, 44, 1375-1383.	2.0	37
71	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
72	Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF- $\beta$ 1 dependent and TGF- $\beta$ 1 independent pathways. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1504-1513.	0.7	36

#	ARTICLE	IF	CITATIONS
73	A Combination of Biocompatible Peritoneal Dialysis Solutions and Residual Renal Function, Peritoneal Transport, and Inflammation Markers: A Randomized Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2012, 60, 966-975.	1.9	36
74	Sulodexide Decreases Albuminuria and Regulates Matrix Protein Accumulation in C57BL/6 Mice with Streptozotocin-Induced Type I Diabetic Nephropathy. <i>PLoS ONE</i> , 2013, 8, e54501.	2.5	36
75	Cost Comparison Between Mycophenolate Mofetil and Cyclophosphamide-Azathioprine in the Treatment of Lupus Nephritis. <i>Journal of Rheumatology</i> , 2009, 36, 76-81.	2.0	35
76	Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2015, 24, 274-284.	2.9	35
77	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
78	Comparison of the Second-Generation Digene Hybrid Capture Assay with the Branched-DNA Assay for Measurement of Hepatitis B Virus DNA in Serum. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2461-2465.	3.9	35
79	Intrinsic cells: mesothelial cells – central players in regulating inflammation and resolution. <i>Peritoneal Dialysis International</i> , 2009, 29 Suppl 2, S21-7.	2.3	35
80	Pilot study of pegylated interferonα€alpha 2a in dialysis patients with chronic hepatitis C virus infection. <i>Nephrology</i> , 2007, 12, 11-17.	1.6	34
81	Overview of lupus nephritis management guidelines and perspective from Asia. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 625-636.	1.9	34
82	Risks and outcomes of peritonitis after flexible colonoscopy in CAPD patients. <i>Peritoneal Dialysis International</i> , 2007, 27, 560-4.	2.3	33
83	Colonic Diverticulosis as a Risk Factor for Peritonitis in Chinese Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2010, 30, 187-191.	2.3	32
84	Dyslipidaemia in patients with lupus nephritis. <i>Nephrology</i> , 2011, 16, 511-517.	1.6	32
85	Noninvasive assessment of kidney allograft fibrosis with shear wave elastography: A radiological–pathological correlation analysis. <i>International Journal of Urology</i> , 2018, 25, 450-455.	1.0	30
86	Mesothelial cells. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S110-5.	2.3	30
87	Three SNPs in chromosome 11q23.3 are independently associated with systemic lupus erythematosus in Asians. <i>Human Molecular Genetics</i> , 2014, 23, 524-533.	2.9	29
88	Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 891-898.	0.9	28
89	Molecular and Immunological Basis of Tubulo-Interstitial Injury in Lupus Nephritis: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 149-163.	6.5	28
90	Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1565-1576.	0.7	28

#	ARTICLE	IF	CITATIONS
91	Prospective Study on Lamivudine-Resistant Hepatitis B in Renal Allograft Recipients. American Journal of Transplantation, 2004, 4, 1103-1109.	4.7	26
92	Impact of a Low-Glucose Peritoneal Dialysis Regimen on Fibrosis and Inflammation Biomarkers. Peritoneal Dialysis International, 2015, 35, 147-158.	2.3	26
93	Binding of anti-dsDNA antibodies to proximal tubular epithelial cells contributes to renal tubulointerstitial inflammation. Clinical Science, 2017, 131, 49-67.	4.3	25
94	Lupus nephritis: An update on treatments and pathogenesis. Nephrology, 2018, 23, 80-83.	1.6	25
95	Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice. Autoimmunity, 2015, 48, 471-487.	2.6	24
96	Clinical Outcomes and Clinico-pathological Correlations in Lupus Nephritis with Kidney Biopsy Showing Thrombotic Microangiopathy. Journal of Rheumatology, 2019, 46, 1478-1484.	2.0	24
97	Vaccination in patients with chronic kidney disease—Review of current recommendations and recent advances. Nephrology, 2021, 26, 5-11.	1.6	24
98	Reduction of Perlecan Synthesis and Induction of TGF- $\beta$ 1 in Human Peritoneal Mesothelial Cells Due to High Dialysate Glucose Concentration: Implication in Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 1178-1188.	6.1	23
99	Renal cell carcinoma of native kidney in Chinese renal transplant recipients: a report of 12 cases and a review of the literature. International Urology and Nephrology, 2011, 43, 675-680.	1.4	23
100	Prevalence of cognitive impairment among peritoneal dialysis patients: a systematic review and meta-analysis. Clinical and Experimental Nephrology, 2019, 23, 1221-1234.	1.6	22
101	Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis. Clinical Science, 2019, 133, 1721-1744.	4.3	22
102	Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. Nephrology Dialysis Transplantation, 2020, 35, 810-818.	0.7	22
103	Response to adefovir or entecavir in renal allograft recipients with hepatitis flare due to lamivudine-resistant hepatitis B. Clinical Transplantation, 2010, 24, 207-212.	1.6	21
104	The Role of Hyaluronan and CD44 in the Pathogenesis of Lupus Nephritis. Autoimmune Diseases, 2012, 2012, 1-9.	0.6	21
105	Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. F1000Research, 2017, 6, 874.	1.6	21
106	Entecavir treatment in kidney transplant recipients infected with hepatitis B. Clinical Transplantation, 2014, 28, 1010-1015.	1.6	20
107	EFFICACY OF FAMCICLOVIR IN THE TREATMENT OF LAMIVUDINE RESISTANCE RELATED TO AN ATYPICAL HEPATITIS B VIRUS MUTANT. Transplantation, 2002, 73, 148-151.	1.0	20
108	Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2022, 9, 827859.	2.6	20



#	ARTICLE	IF	CITATIONS
109	Procalcitonin Fails to Differentiate Inflammatory Status or Predict Long-Term Outcomes in Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2008, 28, 377-384.	2.3	19
110	Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 670-678.	2.4	18
111	Retroperitoneal Leakage as a Cause of Acute Ultrafiltration Failure: Its Associated Risk Factors in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2009, 29, 542-547.	2.3	18
112	Rapamycin Attenuates the Severity of Murine Adriamycin Nephropathy. <i>American Journal of Nephrology</i> , 2009, 29, 342-352.	3.1	18
113	Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, 202-206.	0.9	18
114	A Longitudinal Study on the Prevalence and Risk Factors for Depression and Anxiety, Quality of Life, and Clinical Outcomes in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2019, 39, 74-82.	2.3	17
115	MicroRNAs in Lupus Nephritis—Role in Disease Pathogenesis and Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10737.	4.1	17
116	Preventing renal failure in patients with severe lupus nephritis. <i>Kidney International</i> , 2005, 67, S116-S119.	5.2	16
117	A Prospective Randomized Study Comparing Tenckhoff Catheters Inserted using the Triple Incision Method with Standard Swan Neck Catheters. <i>Peritoneal Dialysis International</i> , 2010, 30, 56-62.	2.3	16
118	Epistatic Interaction between Genetic Variants in Susceptibility Gene <i>ETS1</i> Correlates with IL-17 Levels in SLE Patients. <i>Annals of Human Genetics</i> , 2013, 77, 344-350.	0.8	16
119	A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. <i>F1000Research</i> , 2020, 9, 905.	1.6	16
120	Evolution of hepatitis B management in kidney transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 468.	3.3	16
121	Health-related quality of life and health utility of Chinese patients undergoing nocturnal home haemodialysis in comparison with other modes of dialysis. <i>Nephrology</i> , 2019, 24, 630-637.	1.6	15
122	Preemptive immunosuppressive treatment for asymptomatic serological reactivation may reduce renal flares in patients with lupus nephritis: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 467-473.	0.7	15
123	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.	3.1	15
124	Glycosaminoglycans and proteoglycans: overlooked entities?. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S104-9.	2.3	15
125	Mannose binding lectin level and polymorphism in patients on long-term peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2489-2496.	0.7	14
126	Peritoneal Proteoglycans: Much more than Ground Substance. <i>Peritoneal Dialysis International</i> , 2007, 27, 375-390.	2.3	14



#	ARTICLE	IF	CITATIONS
127	Gene-Based Meta-Analysis of Genome-Wide Association Study Data Identifies Independent Single-Nucleotide Polymorphisms in <i>ANXA6</i> as Being Associated With Systemic Lupus Erythematosus in Asian Populations. <i>Arthritis and Rheumatology</i> , 2015, 67, 2966-2977.	5.6	14
128	Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2016, 32, 1097-1108.	1.9	14
129	Annexin II-binding immunoglobulins in patients with lupus nephritis and their correlation with disease manifestations. <i>Clinical Science</i> , 2017, 131, 653-671.	4.3	14
130	miR-200c Prevents TGF- $\beta$ 1-Induced Epithelial-to-Mesenchymal Transition and Fibrogenesis in Mesothelial Cells by Targeting ZEB2 and Notch1. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 78-91.	5.1	14
131	Anti-fibrotic effect of decorin in peritoneal dialysis and PD-associated peritonitis. <i>EBioMedicine</i> , 2020, 52, 102661.	6.1	14
132	Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis. <i>Lupus</i> , 2021, 30, 1039-1050.	1.6	14
133	Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil. <i>Lupus</i> , 2014, 23, 678-683.	1.6	13
134	Developing the ethical framework of end-stage kidney disease care: from practice to policy. <i>Kidney International Supplements</i> , 2020, 10, e72-e77.	14.2	13
135	The role of kidney transplantation as a component of integrated care for chronic kidney disease. <i>Kidney International Supplements</i> , 2020, 10, e78-e85.	14.2	13
136	Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy. <i>BMC Nephrology</i> , 2020, 21, 42.	1.8	13
137	Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3243-3251.	0.7	12
138	Histological reclassification of lupus nephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 561-566.	2.0	11
139	<i>Streptococcus Bovis</i> Peritonitis Complicating Peritoneal Dialysis—A Review of 10 Years' Experience. <i>Peritoneal Dialysis International</i> , 2012, 32, 55-59.	2.3	11
140	Treatment of lupus nephritis: practical issues in Asian countries. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 138-145.	1.9	11
141	Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays. <i>Hepatology</i> , 1993, 17, 5-8.	7.3	11
142	Management of hepatitis B reactivation in patients with lupus nephritis. <i>Rheumatology International</i> , 2009, 29, 1273-1277.	3.0	10
143	Self-Care Peritoneal Dialysis Patients with Cognitive Impairment Have a Higher Risk of Peritonitis in the Second Year. <i>Peritoneal Dialysis International</i> , 2019, 39, 51-58.	2.3	10
144	Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis. <i>Rheumatology</i> , 2021, 60, 737-750.	1.9	10

#	ARTICLE	IF	CITATIONS
145	Demographics and long-term outcomes of children with end-stage kidney disease: A 20-year territory-wide study. <i>Nephrology</i> , 2022, 27, 171-180.	1.6	10
146	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.	6.1	10
147	Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment. <i>Renal Failure</i> , 2013, 35, 942-945.	2.1	9
148	Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis. <i>Lupus</i> , 2016, 25, 46-53.	1.6	9
149	Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis. <i>Kidney International Reports</i> , 2022, 7, 516-525.	0.8	9
150	B Cells in Primary Membranous Nephropathy: Escape from Immune Tolerance and Implications for Patient Management. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13560.	4.1	9
151	High Prevalence of Vitamin D Insufficiency in Southern Chinese Renal Transplant Recipients. <i>Renal Failure</i> , 2012, 34, 980-984.	2.1	8
152	New Onset Psoriasis after rituximab for Treatment of Idiopathic Membranous Nephropathy. <i>Nephrology</i> , 2014, 19, 60-60.	1.6	8
153	Palliative Care Consultation in Advanced Chronic Kidney Disease with Pain. <i>Journal of Palliative Medicine</i> , 2018, 21, 809-814.	1.1	8
154	Case of relapsing COVID-19 in a kidney transplant recipient. <i>Nephrology</i> , 2020, 25, 933-936.	1.6	8
155	B Cell Subsets and Cellular Signatures and Disease Relapse in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2020, 11, 1732.	4.8	8
156	Studying the effects of new peritoneal dialysis solutions on the peritoneum. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S87-93.	2.3	8
157	INCREASED SURVIVAL OF MESOTHELIAL CELLS FROM THE PERITONEUM IN PERITONEAL DIALYSIS FLUID. <i>Cell Biology International</i> , 2001, 25, 445-450.	3.0	7
158	Tuberculous lymphadenitis in patients undergoing continuous ambulatory peritoneal dialysis. <i>International Urology and Nephrology</i> , 2007, 39, 971-974.	1.4	6
159	Recent Progress in the Treatment of Proliferative Lupus Nephritis. <i>American Journal of Medicine</i> , 2012, 125, 642-648.	1.5	6
160	<i>Burkholderia cepacia</i> "An Uncommon Cause of Exit-Site Infection in a Peritoneal Dialysis Patient. <i>Peritoneal Dialysis International</i> , 2014, 34, 471-472.	2.3	6
161	Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 67.	3.5	6
162	Peritoneal proteoglycans: much more than ground substance. <i>Peritoneal Dialysis International</i> , 2007, 27, 375-90.	2.3	6

#	ARTICLE	IF	CITATIONS
163	What is the ideal duration of maintenance therapy for lupus nephritis?. Expert Review of Clinical Immunology, 2022, 18, 425-427.	3.0	6
164	Correlation study between spot urine protein-to-creatinine ratio and 24-hour urine protein measurement in 174 patients for proteinuria assessment. Hong Kong Journal of Nephrology, 2011, 13, 51-54.	0.0	5
165	<i>Burkholderia Cepacia</i> Exit-Site Infection in Peritoneal Dialysis Patientsâ€”Clinical Characteristics and Treatment Outcomes. Peritoneal Dialysis International, 2016, 36, 390-394.	2.3	5
166	TRANSHEPATIC PLACEMENT OF HAEMODIALYSIS CATHETER: A SOLUTION FOR VASCULAR ACCESS EXHAUSTION. Nephrology, 2010, 15, 661-662.	1.6	4
167	Dialysis practice from the English NHS to the orient. CKJ: Clinical Kidney Journal, 2013, 6, 554-555.	2.9	4
168	Arthrobacter sanguinis: An uncommon cause of peritonitis in a peritoneal dialysis patient. Nephrology, 2015, 20, 868-868.	1.6	4
169	Predictive value of plasma neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive care unit patients after major nonâ€œcardiac surgery. Nephrology, 2015, 20, 375-382.	1.6	4
170	Severe liver failure due to influenza A infection in a hemodialysis patient. Hemodialysis International, 2016, 20, E16-8.	0.9	4
171	Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience. Nephrology, 2016, 21, 438-441.	1.6	4
172	Long-term data on entecavir treatment for treatment-naïve or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients. Transplant Infectious Disease, 2019, 21, e13143.	1.7	4
173	Mesangial Cell-Binding Activity of Serum Immunoglobulin G in Patients with Lupus Nephritis. PLoS ONE, 2014, 9, e101987.	2.5	4
174	Treatment of acute kidney injury complicating septic shock with EMIc2 high-cutoff hemofilter: Case series. Indian Journal of Critical Care Medicine, 2017, 21, 751-757.	0.9	4
175	An Unusual Organism for PD-Related Peritonitis: <i>Hafnia Alvei</i> . Peritoneal Dialysis International, 2010, 30, 254-255.	2.3	3
176	Renal allograft tissue: its new role in patient management. Histopathology, 2012, 60, 1160-1162.	2.9	3
177	Successful Treatment of Pulmonary <i>Rhizopus</i> Infection with Surgical Resection and Posaconazole in a Renal Transplant Recipient. Nephrology, 2013, 18, 74-75.	1.6	3
178	Cortical necrosis in a kidney transplant recipient due to leptospirosis. Nephrology, 2014, 19, 257-258.	1.6	3
179	Chronotropic incompetence, echocardiographic abnormalities and exercise intolerance in renal transplant recipients. Journal of Nephrology, 2014, 27, 451-456.	2.0	3
180	Acute Phosphate Nephropathy: An Under-Recognized Complication Leading to Impaired Allograft Function After Renal Transplant. Nephrology, 2016, 21, 980-981.	1.6	3

#	ARTICLE	IF	CITATIONS
181	Acute kidney injury in a renal transplant recipient due to concomitant use of vancomycin and foscarnet. <i>Nephrology</i> , 2017, 22, 821-822.	1.6	3
182	Effect of Combined Mycophenolate and Rapamycin Treatment on Kidney Fibrosis in Murine Lupus Nephritis. <i>Frontiers in Pharmacology</i> , 2022, 13, 866077.	3.5	3
183	PERINEPHRIC HEMATOMA AND MASSIVE GASTROINTESTINAL HEMORRHAGE (GIB) COMPLICATING POLYARTERITIS NODOSA (PAN). <i>Renal Failure</i> , 2000, 22, 379-384.	2.1	2
184	Histologic deterioration and more flares: The case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 702-704.	6.7	2
185	Lupus Nephritis—An Enriching Opus. <i>Hong Kong Journal of Nephrology</i> , 2009, 11, 5-8.	0.0	2
186	Dosing regimen and tolerability of methoxy polyethylene glycol—epoetin beta in Chinese dialysis patients. <i>Nephrology</i> , 2013, 18, 533-538.	1.6	2
187	Epistaxis in a kidney transplant recipient: An uncommon presentation of post-transplant lymphoproliferative disease. <i>Nephrology</i> , 2013, 18, 531-531.	1.6	2
188	Invasive fungal rhinosinusitis presenting as Bell's palsy in a kidney and liver transplant recipient. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 910-911.	1.7	2
189	Tissue Remodeling and Inflammation during Peritoneal Dialysis: Catheter versus Fluid. <i>Peritoneal Dialysis International</i> , 2010, 30, 274-276.	2.3	1
190	Severe hypocalcaemia and hyperphosphataemia caused by oral sodium phosphate fleet solution in a haemodialysis patient after parathyroidectomy. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 248-250.	2.9	1
191	Kidney Allograft Abscess: An Unusual Cause of Peritonitis in a Patient on Peritoneal Dialysis. <i>Nephrology</i> , 2016, 21, 266-266.	1.6	1
192	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3630-3641.	2.3	1
193	Determinants of patient survival in systemic lupus erythematosus—focusing on lupus nephritis. <i>Ethnicity and Disease</i> , 2006, 16, S2-66-9.	2.3	1
194	Mycophenolate mofetil as treatment for lupus nephritis. <i>APLAR Journal of Rheumatology</i> , 2004, 7, 268-271.	0.2	0
195	Mycophenolate mofetil in the treatment of lupus nephritis: an appraisal of recent data. <i>APLAR Journal of Rheumatology</i> , 2006, 9, 403-407.	0.2	0
196	Emodin ameliorates glucose-induced fibronectin synthesis in human peritoneal mesothelial cells by inhibiting PKC $\alpha$ activation. <i>International Journal of Experimental Pathology</i> , 2004, 85, A15.	1.3	0
197	Peritoneal fibrosis and the putative role of decorin. <i>Hong Kong Journal of Nephrology</i> , 2013, 15, 55-61.	0.0	0
198	An overview of current and future treatment methods for lupus nephritis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 169-179.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Antiviral treatment for chronic hepatitis B infection in renal transplant recipients. Hong Kong Journal of Nephrology, 2015, 17, 8-13.	0.0	0
200	SP165RISK FACTORS FOR RENAL FLARES IN LUPUS NEPHRITIS AND THE IMPACT OF MYCOPHENOLIC ACID TREATMENT ON RELAPSE. Nephrology Dialysis Transplantation, 2016, 31, i140-i141.	0.7	0
201	MP122THE IMPACT OF PRE-EMPTIVE INCREASE IN IMMUNOSUPPRESSIVE TREATMENTS ON SUBSEQUENT RISK OF RENAL FLARES IN LUPUS NEPHRITIS PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i383-i383.	0.7	0
202	Secondary atypical mycobacterial infection after peritoneal catheter removal. International Wound Journal, 2016, 13, 1021-1022.	2.9	0
203	Risk factors and prognosis of late acute rejection in Chinese kidney transplant recipients. Nephrology, 2017, 22, 985-992.	1.6	0
204	SaO017ANTIPHOSPHOLIPID ANTIBODIES IN LUPUS NEPHRITIS - A SINGLE CENTRE EXPERIENCE. Nephrology Dialysis Transplantation, 2018, 33, i322-i322.	0.7	0
205	FP165CLINICAL CHARACTERISTICS AND OUTCOMES OF LUPUS NEPHRITIS PATIENTS WITH KIDNEY BIOPSY SHOWING THROMBOTIC MICROANGIOPATHY. Nephrology Dialysis Transplantation, 2018, 33, i85-i85.	0.7	0
206	Clinical practice guidelines for the provision of renal service in Hong Kong: Infection Control in Renal Service. Nephrology, 2019, 24, 98-129.	1.6	0
207	P1198CATHETER-RELATED INFECTIONS DUE TO SERRATIA SPECIES IN PATIENTS RECEIVING PERITONEAL DIALYSIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
208	SO077A PROSPECTIVE RANDOMIZED STUDY ON PRE-EMPTIVE IMMUNOSUPPRESSIVE TREATMENT IN LUPUS NEPHRITIS PATIENTS WITH ASYMPTOMATIC SEROLOGICAL REACTIVATION. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
209	Conversion from Aranesp® to NESP Â® in dialysis patientsâ€™Exploration of dosing strategies and the feasibility of extending the dosing interval. Nephrology, 2021, 26, 733-741.	1.6	0